Protein-mimicking compounds for Lewy Body Dementia
Official title: Synthetic protein mimetics as potential therapeutics for Lewy Body Dementia
Funded at University of Denver (Colorado Seminary) · NIH-11195029 · Data updated 2026-11-12
This work is developing small protein-like molecules designed to block the harmful brain protein clumps that drive Lewy Body Dementia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Denver (Colorado Seminary) NIH-funded |
| Lab location | 1 site (Denver, United States) |
| Project start | September 19, 2024 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $704,875 |
| NIH project number | 5R61NS137824-02 |
| Project ID | NIH-11195029 on NIH RePORTER |
Who could benefit from this research
✓Could help
When this program reaches clinical trials, ideal candidates would be people diagnosed with or at high risk for Lewy Body Dementia, though the current grant supports preclinical work rather than patient enrollment.
✕Less likely to help
People with dementias not driven by alpha-synuclein pathology (for example, pure Alzheimer's disease without Lewy bodies) may not benefit from these specific compounds.
What this research studies
As someone worried about Lewy Body Dementia, this project is creating and improving synthetic molecules called oligopyridylamides (OPs) that mimic protein surfaces to stop alpha-synuclein from clumping. The team has already shown these OPs block clumps in cells, neurons, C. elegans, and mice and that lead compounds can cross the blood-brain barrier without obvious toxicity. Over the next years they will optimize the chemistry and drug-like properties, test dosing and safety, and study effects on Lewy body formation in animal models. The goal is to prepare safe, effective candidates that could move into human trials in the future.
Why it matters
Potential benefit: If successful, this work could lead to new medicines that prevent or slow Lewy Body Dementia by stopping alpha-synuclein aggregation.
How similar studies have gone: Related preclinical studies targeting alpha-synuclein have shown promise in lab and animal models, but human trial evidence for this approach remains limited.
Where this research is happening
-
University of Denver (Colorado Seminary)
Denver, United States Active
Researchers
- Principal investigator: Kumar, Sunil — University of Denver (Colorado Seminary)
- Study coordinator: Kumar, Sunil
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Synthetic protein mimetics to treat Lewy Body Dementia
A new therapeutic approach using engineered protein-like molecules to block the harmful protein clumps that cause Lewy Body Dementia.
-
Dementia care staff study: adapting a US survey for use in many countries
A study is adapting and testing a survey for dementia care workers in the US, Brazil, Switzerland, and Ghana to help understand why workers stay in their jobs and how to improve care.
-
Dementia care staff study: adapting a survey for use in many countries
A multinational study will adapt and test a U.S. dementia-care worker survey in Brazil, Switzerland, and Ghana to help understand why staff stay in or leave long-term care settings.
-
Study of Dementia Care Staff in 4 Countries: Adapting Caregiver Surveys Across Cultures
A multinational project will adapt and test a dementia care worker survey so researchers can compare care environments across the US, Brazil, Switzerland, and Ghana.
-
New biomarkers to distinguish LATE from Alzheimer’s disease in dementia
A study to develop blood and CSF tests that can tell apart LATE from Alzheimer’s disease in people with dementia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.